Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07559331 Dexamethasone Sodium Phosphate Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07559331 Dexamethasone Sodium Phosphate Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07559331 clinical trial report covering Dexamethasone Sodium Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261671 Changji'an Capsule Irritable bowel syndrome with diarrhea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261671 Changji'an Capsule Irritable bowel syndrome with diarrhea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261671 clinical trial report covering Changji'an Capsule, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07559513 Garetosmab Myositis Ossificans Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07559513 Garetosmab Myositis Ossificans Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07559513 clinical trial report covering Garetosmab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07562022 Lenalidomide Refractory Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07562022 Lenalidomide Refractory Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07562022 clinical trial report covering Lenalidomide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07562152 Albumin-Bound Paclitaxel Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07562152 Albumin-Bound Paclitaxel Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07562152 clinical trial report covering Albumin-Bound Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07560306 [64Cu]FBP8 Thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07560306 [64Cu]FBP8 Thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07560306 clinical trial report covering [64Cu]FBP8, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07565428 Aripiprazole Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07565428 Aripiprazole Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07565428 clinical trial report covering Aripiprazole, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07566052 Setidegrasib KRAS G12D mutation Non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07566052 Setidegrasib KRAS G12D mutation Non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07566052 clinical trial report covering Setidegrasib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07566195 Tozorakimab Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07566195 Tozorakimab Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07566195 clinical trial report covering Tozorakimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07566156 Enfortumab Vedotin-ejfv Muscle Invasive Bladder Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07566156 Enfortumab Vedotin-ejfv Muscle Invasive Bladder Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07566156 clinical trial report covering Enfortumab Vedotin-ejfv, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07564414 Semaglutide/Cagrilintide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07564414 Semaglutide/Cagrilintide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07564414 clinical trial report covering Semaglutide/Cagrilintide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07563881 RAP-219 Seizures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07563881 RAP-219 Seizures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07563881 clinical trial report covering RAP-219, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →